imunaris is a forward-thinking Swiss startup committed to facilitating commercial access for pharmaceuticals, medical devices, and diagnostics. With a focus on agile and efficient methods, we offer tailored solutions to conquer the complexities of the Swiss healthcare market.

nuantic offers AI-guided lead optimization to biotech and pharma customers developing protein- and peptide-based therapeutics. We're able to optimize affinity, developability and aspects of immunogenicity with outstanding success rates with 10x less effort as compared to traditional methods.

FoRx Therapeutics is a clinical-stage company that develops next-generation small molecule therapeutics targeting DNA Replication Stress pathways for anti-cancer therapy. The lead program is a highly potent and selective PARG inhibitor, FORX-428, which  moved into clinical Phase 1 in H2 2025.